Superior safety profile for decitabine vs chemotherapy for older patient with AML

Acute myeloid leukemia (AML) predominantly occurs in older adults over 65, who often have a lower tolerance to conventional induction chemotherapy (IC) than younger patients. Despite treatment with IC, older patients with AML have poor long-term survival without hematopoietic stem cell transplantation (HSCT).